Zdrowie i gospodarka · 16/03/2011
Regulatory Body Hosts Public Workshop to Discuss Strategies for Minimizing Blood Clot Risk in IVIG Products
The FDA is hosting a public workshop to discuss potential procoagulant activity in Immune Globulin Intravenous (IVIG) products and strategies to mitigate this risk, following recent reports of adverse events associated with these treatments.